IL178003A - Acid 1– [2– (4 – amino – 3 – chloro – benzoylamino) –3,3 – dimethyl – butyryl] –pyrrolidine – 2 – carboxylic (2 – ethoxy – 5 – oxo – tetrahydro – furan – 3-il) - Affluent, its isomers, and process for its preparation - Google Patents
Acid 1– [2– (4 – amino – 3 – chloro – benzoylamino) –3,3 – dimethyl – butyryl] –pyrrolidine – 2 – carboxylic (2 – ethoxy – 5 – oxo – tetrahydro – furan – 3-il) - Affluent, its isomers, and process for its preparationInfo
- Publication number
- IL178003A IL178003A IL178003A IL17800306A IL178003A IL 178003 A IL178003 A IL 178003A IL 178003 A IL178003 A IL 178003A IL 17800306 A IL17800306 A IL 17800306A IL 178003 A IL178003 A IL 178003A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- mixture
- purifying
- solvent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 13
- SJDDOCKBXFJEJB-UHFFFAOYSA-N 1-[2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-n-(2-ethoxy-5-oxooxolan-3-yl)pyrrolidine-2-carboxamide Chemical compound CCOC1OC(=O)CC1NC(=O)C1N(C(=O)C(NC(=O)C=2C=C(Cl)C(N)=CC=2)C(C)(C)C)CCC1 SJDDOCKBXFJEJB-UHFFFAOYSA-N 0.000 title 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 6
- 229910052763 palladium Inorganic materials 0.000 claims 5
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- -1 bisphosphine Chemical compound 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003444 phase transfer catalyst Substances 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 claims 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55248004P | 2004-03-12 | 2004-03-12 | |
| PCT/US2005/008251 WO2005090334A2 (en) | 2004-03-12 | 2005-03-11 | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL178003A0 IL178003A0 (en) | 2006-12-31 |
| IL178003A true IL178003A (en) | 2012-04-30 |
Family
ID=34962478
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL178003A IL178003A (en) | 2004-03-12 | 2006-09-11 | Acid 1– [2– (4 – amino – 3 – chloro – benzoylamino) –3,3 – dimethyl – butyryl] –pyrrolidine – 2 – carboxylic (2 – ethoxy – 5 – oxo – tetrahydro – furan – 3-il) - Affluent, its isomers, and process for its preparation |
| IL218487A IL218487A (en) | 2004-03-12 | 2012-03-05 | Processes for the production of protected derivatives of ((2-alkyloxy-5-oxo-2,5-dihydrofuran-3-ram) carbamoyl) pyrrolidine |
| IL218488A IL218488A0 (en) | 2004-03-12 | 2012-03-05 | Processes and intermediates |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218487A IL218487A (en) | 2004-03-12 | 2012-03-05 | Processes for the production of protected derivatives of ((2-alkyloxy-5-oxo-2,5-dihydrofuran-3-ram) carbamoyl) pyrrolidine |
| IL218488A IL218488A0 (en) | 2004-03-12 | 2012-03-05 | Processes and intermediates |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7381827B2 (https=) |
| EP (3) | EP2399916B1 (https=) |
| JP (2) | JP4898658B2 (https=) |
| KR (2) | KR101135765B1 (https=) |
| CN (3) | CN1950364B (https=) |
| AR (1) | AR048008A1 (https=) |
| AU (1) | AU2005223767B2 (https=) |
| BR (1) | BRPI0508609B8 (https=) |
| CA (3) | CA2843066C (https=) |
| DK (3) | DK1725548T3 (https=) |
| ES (3) | ES2532967T3 (https=) |
| HU (1) | HUE024556T2 (https=) |
| IL (3) | IL178003A (https=) |
| PL (4) | PL2399915T3 (https=) |
| PT (3) | PT2399916E (https=) |
| RU (2) | RU2433127C2 (https=) |
| SG (2) | SG150546A1 (https=) |
| SI (3) | SI2399915T1 (https=) |
| TW (3) | TW201200508A (https=) |
| WO (1) | WO2005090334A2 (https=) |
| ZA (1) | ZA200607605B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
| US7652153B2 (en) * | 2004-02-27 | 2010-01-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2005115362A1 (en) * | 2004-05-15 | 2005-12-08 | Vertex Pharmaceuticals Incorporated | Treating seizures using ice inhibitors |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| CN101534824A (zh) * | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| DK2114924T3 (da) * | 2007-02-27 | 2012-04-10 | Vertex Pharma | Co-krystaller og farmaceutiske sammensætninger omfattende disse |
| JP2010519329A (ja) | 2007-02-27 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ阻害剤 |
| CN101835774B (zh) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
| WO2010017408A1 (en) | 2008-08-06 | 2010-02-11 | The Buck Institute For Age Research | Caspase inhibitors and uses thereof |
| US9113848B2 (en) * | 2010-02-03 | 2015-08-25 | Covidien Lp | Surgical retrieval apparatus |
| JP5769655B2 (ja) * | 2012-03-30 | 2015-08-26 | ユニ・チャーム株式会社 | 吸収性物品 |
| CN103193572B (zh) * | 2013-04-07 | 2015-06-17 | 山东大学 | 一种拉唑类化合物单一对映体的分离方法 |
| PT3558335T (pt) | 2016-12-23 | 2023-07-20 | Casp Aid Inc | Inibição da caspase-1 e sua utilização na prevenção e tratamento de doenças neurológicas |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
| BE1008343A3 (nl) | 1994-05-06 | 1996-04-02 | Dsm Nv | Bidentaat fosfineligand |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| ES2150696T3 (es) * | 1995-11-09 | 2000-12-01 | Akzo Pq Silica Vof | Silicato de sodio compactado. |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| DE69718012T2 (de) | 1996-09-12 | 2003-09-25 | Idun Pharmaceuticals, Inc. | C-terminale modifizierte (n-substituierte)-2-indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie |
| AU738048B2 (en) | 1996-09-12 | 2001-09-06 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors |
| US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| NZ330451A (https=) | 1996-09-12 | 2000-01-28 | Idun Pharmaceuticals Inc | |
| US5968927A (en) | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| US5919790A (en) | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| CA2268086A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | Sulfonamide interleukin-1.beta. converting enzyme inhibitors |
| AU738341B2 (en) | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| FR2766188B1 (fr) | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| WO1999031066A1 (en) | 1997-12-18 | 1999-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridones as src family sh2 domain inhibitors |
| PT1049703E (pt) | 1998-01-20 | 2003-06-30 | Warner Lambert Co | Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo |
| TWI243828B (en) * | 1998-03-19 | 2005-11-21 | Vertex Pharma | Inhibitors of caspases |
| US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| JP2002539193A (ja) | 1999-03-16 | 2002-11-19 | メルク フロスト カナダ アンド カンパニー | カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類 |
| AU3876600A (en) | 1999-03-16 | 2000-10-04 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| US6355618B1 (en) | 1999-04-09 | 2002-03-12 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| ATE344249T1 (de) | 1999-07-19 | 2006-11-15 | Merck Frosst Canada Ltd | Pyrazinone, diese verbindungen enthaltende zusammenstellungen |
| DE60010675T2 (de) | 1999-08-06 | 2005-06-16 | Vertex Pharmaceuticals Inc., Cambridge | Caspase inhibitoren und deren verwendung |
| US6495522B1 (en) | 1999-08-27 | 2002-12-17 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| AU2001249619B2 (en) | 2000-03-29 | 2006-08-17 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
| EP1278737B1 (en) * | 2000-04-24 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
| TWI291462B (en) | 2000-04-25 | 2007-12-21 | Daiichi Sankyo Co Ltd | Hydrate crystal of neuraminic acid compound |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| KR20020025959A (ko) | 2000-05-23 | 2002-04-04 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 및 이의 용도 |
| WO2001094351A1 (en) | 2000-06-07 | 2001-12-13 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| DK1385870T3 (da) | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| CA2418720A1 (en) | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| DE60127860T2 (de) | 2000-11-21 | 2008-01-17 | Vertex Pharmaceuticals Inc., Cambridge | Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung |
| GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
| US20030096737A1 (en) | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| WO2002094263A2 (en) | 2001-05-23 | 2002-11-28 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| CA2449504A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| JP2005509028A (ja) | 2001-10-09 | 2005-04-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法 |
| US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| AU2003225088A1 (en) | 2002-04-19 | 2003-11-03 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| US7138395B2 (en) | 2002-06-10 | 2006-11-21 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
| US7001899B2 (en) | 2002-06-10 | 2006-02-21 | The Procter & Gamble Company | Interleukin converting enzyme inhibitors |
| US7041696B2 (en) | 2002-06-17 | 2006-05-09 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
| PL374598A1 (en) | 2002-06-28 | 2005-10-31 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| US7652153B2 (en) * | 2004-02-27 | 2010-01-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
-
2005
- 2005-03-11 EP EP11178128.2A patent/EP2399916B1/en not_active Expired - Lifetime
- 2005-03-11 HU HUE05728092A patent/HUE024556T2/hu unknown
- 2005-03-11 EP EP11178126.6A patent/EP2399915B1/en not_active Expired - Lifetime
- 2005-03-11 CA CA2843066A patent/CA2843066C/en not_active Expired - Fee Related
- 2005-03-11 PT PT11178128T patent/PT2399916E/pt unknown
- 2005-03-11 DK DK05728092.7T patent/DK1725548T3/en active
- 2005-03-11 PL PL11178126T patent/PL2399915T3/pl unknown
- 2005-03-11 SG SG200901306-1A patent/SG150546A1/en unknown
- 2005-03-11 PL PL11178128T patent/PL2399916T3/pl unknown
- 2005-03-11 AU AU2005223767A patent/AU2005223767B2/en not_active Ceased
- 2005-03-11 ES ES11178126.6T patent/ES2532967T3/es not_active Expired - Lifetime
- 2005-03-11 PT PT57280927T patent/PT1725548E/pt unknown
- 2005-03-11 PT PT111781266T patent/PT2399915E/pt unknown
- 2005-03-11 ES ES05728092.7T patent/ES2533991T3/es not_active Expired - Lifetime
- 2005-03-11 RU RU2006136032/04A patent/RU2433127C2/ru active
- 2005-03-11 CA CA2768700A patent/CA2768700C/en not_active Expired - Fee Related
- 2005-03-11 EP EP05728092.7A patent/EP1725548B1/en not_active Expired - Lifetime
- 2005-03-11 KR KR1020067021136A patent/KR101135765B1/ko not_active Expired - Fee Related
- 2005-03-11 CN CN2005800144933A patent/CN1950364B/zh not_active Expired - Lifetime
- 2005-03-11 BR BRPI0508609A patent/BRPI0508609B8/pt not_active IP Right Cessation
- 2005-03-11 SI SI200531945T patent/SI2399915T1/sl unknown
- 2005-03-11 US US11/078,147 patent/US7381827B2/en active Active
- 2005-03-11 JP JP2007503066A patent/JP4898658B2/ja not_active Expired - Lifetime
- 2005-03-11 PL PL05728092T patent/PL1725548T3/pl unknown
- 2005-03-11 DK DK11178126T patent/DK2399915T3/en active
- 2005-03-11 WO PCT/US2005/008251 patent/WO2005090334A2/en not_active Ceased
- 2005-03-11 AR ARP050100964A patent/AR048008A1/es not_active Application Discontinuation
- 2005-03-11 SG SG200901309-5A patent/SG150547A1/en unknown
- 2005-03-11 DK DK11178128T patent/DK2399916T3/en active
- 2005-03-11 CN CN2013103410022A patent/CN103467459A/zh active Pending
- 2005-03-11 ES ES11178128.2T patent/ES2532433T3/es not_active Expired - Lifetime
- 2005-03-11 CA CA2559303A patent/CA2559303C/en not_active Expired - Fee Related
- 2005-03-11 PL PL381358A patent/PL381358A1/pl not_active Application Discontinuation
- 2005-03-11 KR KR1020117029981A patent/KR20110137409A/ko not_active Ceased
- 2005-03-11 SI SI200531959T patent/SI1725548T1/sl unknown
- 2005-03-11 CN CN2011100999799A patent/CN102225936B/zh not_active Expired - Lifetime
- 2005-03-11 SI SI200531941T patent/SI2399916T1/sl unknown
- 2005-03-14 TW TW100133524A patent/TW201200508A/zh unknown
- 2005-03-14 TW TW094107737A patent/TWI398426B/zh not_active IP Right Cessation
- 2005-03-14 TW TW101124668A patent/TWI399356B/zh not_active IP Right Cessation
-
2006
- 2006-09-11 IL IL178003A patent/IL178003A/en active IP Right Grant
- 2006-09-11 ZA ZA200607605A patent/ZA200607605B/xx unknown
-
2008
- 2008-03-07 US US12/074,983 patent/US7834200B2/en not_active Expired - Lifetime
-
2010
- 2010-10-12 US US12/902,811 patent/US8293929B2/en not_active Expired - Lifetime
-
2011
- 2011-07-01 RU RU2011127174/04A patent/RU2011127174A/ru not_active Application Discontinuation
- 2011-10-26 JP JP2011235246A patent/JP2012072151A/ja active Pending
-
2012
- 2012-03-05 IL IL218487A patent/IL218487A/en active IP Right Grant
- 2012-03-05 IL IL218488A patent/IL218488A0/en unknown
- 2012-09-20 US US13/623,563 patent/US20130066083A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL178003A (en) | Acid 1– [2– (4 – amino – 3 – chloro – benzoylamino) –3,3 – dimethyl – butyryl] –pyrrolidine – 2 – carboxylic (2 – ethoxy – 5 – oxo – tetrahydro – furan – 3-il) - Affluent, its isomers, and process for its preparation | |
| US12157721B2 (en) | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate | |
| Ashimori et al. | Catalytic asymmetric synthesis of quarternary carbon centers. Palladium-catalyzed formation of either enantiomer of spirooxindoles and related spirocyclics using a single enantiomer of a chiral diphosphine ligand | |
| Schwink et al. | New C2-symmetrical ferrocenyl diamines as ligands for ruthenium catalyzed transfer hydrogenation | |
| Nishikata et al. | Palladium (II)‐Catalyzed 1, 4‐Addition of Arylboronic Acids to β‐Arylenones for Enantioselective Synthesis of 4‐Aryl‐4H‐chromenes | |
| Chen et al. | A new approach to pyrrolocoumarin derivatives by palladium‐catalyzed reactions: expedient construction of polycyclic Lamellarin scaffold | |
| US8507630B2 (en) | Organic inorganic composite material and utilization thereof | |
| Large et al. | C–H Functionalization Strategies in the Naphthalene Series: Site Selections and Functional Diversity | |
| Hayashi et al. | The chiral diamine mediated asymmetric Baylis–Hillman reaction | |
| CN111217848B (zh) | 螺双二氢苯并噻咯二酚类化合物、合成方法及其应用 | |
| CN1439643A (zh) | 螺环双膦配体 | |
| Nguyen et al. | Chiral Phosphoric Acid Catalyzed Enantioselective Transfer Hydrogenation of ortho‐Hydroxybenzophenone N H Ketimines and Applications | |
| Lu et al. | Highly enantioselective catalytic alkynylation of ketones–A convenient approach to optically active propargylic alcohols | |
| Song et al. | Asymmetric synthesis of highly functionalized spirothiazolidinone tetrahydroquinolines via a squaramide-catalyzed cascade reaction | |
| Syu et al. | Design and Synthesis of Chiral Diene Ligands for RhI‐Catalyzed Enantioselective Arylation of N‐DPP‐protected Aldimines: Synthesis of the Antifungal Agent Bifonazole | |
| Yang et al. | Modified palladium-catalyzed regioselective ortho-arylation of sp2 C–H bond substrates with a low catalyst loading | |
| Malkov et al. | New organocatalysts for the asymmetric reduction of imines with trichlorosilane | |
| JP2010248091A (ja) | 不斉触媒およびこれを用いた光学活性アルコール類の製造方法 | |
| CN102503976A (zh) | 一种α-位季碳的α,β-二胺酸衍生物及其合成方法和应用 | |
| CN113135840B (zh) | 一种共轭烯基脒类化合物的合成方法 | |
| CN1285819A (zh) | 制备酮亚胺的新方法 | |
| Lu et al. | Palladium-catalyzed allylation of aminophenol with alkynes to construct C–N bonds | |
| CN103483363A (zh) | 多样性的手性氨基硼酸及其制备方法和应用 | |
| CN113651813A (zh) | 一种2,3-二氢喹啉-4-酮生物活性骨架及其合成方法和应用 | |
| WO2005092830A1 (ja) | 光学活性遷移金属－ジアミン錯体及びこれを用いた光学活性アルコール類の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |